Urinary Epidermal Growth Factor Levels in Cancer Patients
Author Information
Author(s): J.W. Sweetenham, D.E. Davies, S. Warnes, P. Alexander
Primary Institution: C.R.C. Wessex Medical Oncology Unit, Southampton General Hospital
Hypothesis
Does urinary hEGF level differ between patients with breast or colorectal cancer and normal subjects?
Conclusion
The study found no significant difference in urinary hEGF levels between breast cancer patients and normal subjects, and while there was a significant difference for colorectal cancer patients, its biological significance is questionable.
Supporting Evidence
- The study involved 90 participants, including cancer patients and normal subjects.
- Statistical analysis showed a significant difference in hEGF levels for colorectal cancer patients compared to controls.
- No significant difference was found between breast cancer patients and normal subjects.
- Urinary hEGF was measured using a specific two-site ELISA method.
Takeaway
The study looked at a substance in urine that might help find cancer, but it didn't really work for breast or colorectal cancer patients.
Methodology
Urinary hEGF levels were measured using a two-site ELISA in patients with breast and colorectal cancer compared to normal subjects.
Potential Biases
The lack of matched controls could introduce bias, although no significant differences were observed based on age or sex.
Limitations
The control group was not matched for age or sex, which may affect the results.
Participant Demographics
30 normal subjects (18 males, 12 females), 30 with colorectal carcinoma (13 males, 17 females), and 30 with breast carcinoma (0 males, 30 females).
Statistical Information
P-Value
0.004 for colorectal carcinoma vs normal subjects
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website